Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers

Pancreatic cancer is one of the leading causes of cancer-related deaths, for which serological biomarkers are urgently needed. Most discovery-phase studies focus on the use of one biological source for analysis. The present study details the combined mining of pancreatic cancer-related cell line conditioned media and pancreatic juice for identification of putative diagnostic leads. Using strong cation exchange chromatography, followed by LC-MS/MS on an LTQ-Orbitrap mass spectrometer, we extensively characterized the proteomes of conditioned media from six pancreatic cancer cell lines (BxPc3, MIA-PaCa2, PANC1, CAPAN1, CFPAC1, and SU.86.86), the normal human pancreatic ductal epithelial cell line HPDE, and two pools of six pancreatic juice samples from ductal adenocarcinoma patients. All samples were analyzed in triplicate. Between 1261 and 2171 proteins were identified with two or more peptides in each of the cell lines, and an average of 521 proteins were identified in the pancreatic juice pools. In total, 3479 nonredundant proteins were identified with high confidence, of which ∼40% were extracellular or cell membrane-bound based on Genome Ontology classifications. Three strategies were employed for identification of candidate biomarkers: (1) examination of differential protein expression between the cancer and normal cell lines using label-free protein quantification, (2) integrative analysis, focusing on the overlap of proteins among the multiple biological fluids, and (3) tissue specificity analysis through mining of publically available databases. Preliminary verification of anterior gradient homolog 2, syncollin, olfactomedin-4, polymeric immunoglobulin receptor, and collagen alpha-1(VI) chain in plasma samples from pancreatic cancer patients and healthy controls using ELISA, showed a significant increase (p < 0.01) of these proteins in plasma from pancreatic cancer patients. The combination of these five proteins showed an improved area under the receiver operating characteristic curve to CA19.9 alone. Further validation of these proteins is warranted, as is the investigation of the remaining group of candidates.

[1]  D. Gill,et al.  A MICRO-BIURET METHOD FOR ESTIMATING PROTEINS. , 1964, Analytical biochemistry.

[2]  J. Holland,et al.  Elevated serum ribonuclease in patients with pancreatic cancer. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Sedmak,et al.  A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. , 1977, Analytical biochemistry.

[4]  T. Adrian,et al.  Plasma trypsin in chronic pancreatitis and pancreatic adenocarcinoma. , 1979, Clinica chimica acta; international journal of clinical chemistry.

[5]  J. Artigas,et al.  Serum trypsin levels in acute pancreatic and non-pancreatic abdominal conditions. , 1981, Postgraduate medical journal.

[6]  W. Junge,et al.  Detection of colipase in serum and urine of pancreatitis patients. , 1982, Clinica chimica acta; international journal of clinical chemistry.

[7]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.

[8]  E. Engvall,et al.  Type VI Collagen: Studies on Its Localization, Structure, and Biosynthetic Form with Monoclonal Antibodies , 1984, The Journal of biological chemistry.

[9]  R. Timpl Type VI Collagen , 1987 .

[10]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[11]  O. Itkonen,et al.  Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. , 1990, The Journal of laboratory and clinical medicine.

[12]  Tetsuhide Ito,et al.  Clinical Usefulness of Serum Phospholipase A2 Determination in Patients with Pancreatic Diseases , 1991, Pancreas.

[13]  T. Hayakawa,et al.  Serum pancreatic stone protein in pancreatic diseases , 1993, International journal of pancreatology : official journal of the International Association of Pancreatology.

[14]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[15]  F. Real,et al.  The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro , 1998, Oncogene.

[16]  J. Minna,et al.  Comparison of features of human breast cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Aberger,et al.  Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2 , 1998, Mechanisms of Development.

[18]  J. Minna,et al.  Comparison of features of human lung cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Schmid,et al.  Acinar‐Ductal‐Carcinoma Sequence in Transforming Growth Factor‐α Transgenic Mice , 1999 .

[20]  R. Schmid,et al.  Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice. , 1999, Annals of the New York Academy of Sciences.

[21]  A. Bozdağ,et al.  The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. , 2000, Hepato-gastroenterology.

[22]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[23]  J. Ringel,et al.  The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer , 2003, Molecular Cancer.

[24]  W. Antonin,et al.  Loss of the Zymogen Granule Protein Syncollin Affects Pancreatic Protein Synthesis and Transport but Not Secretion , 2002, Molecular and Cellular Biology.

[25]  A. van Dalen,et al.  Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.

[26]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[27]  R. Schmid Acinar-to-ductal metaplasia in pancreatic cancer development. , 2002, The Journal of clinical investigation.

[28]  A. Oyarzábal,et al.  Marcadores tumorales y reactantes de fase aguda en el diagnóstico del cáncer de páncreas , 2003 .

[29]  A. I. Irigoyen Oyarzabal,et al.  [Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]. , 2003, Gastroenterology & hepatology.

[30]  M. Löhr,et al.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.

[31]  L. Wagner,et al.  21. UniGene: A Unified View of the Transcriptome , 2003 .

[32]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Kinzler,et al.  Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.

[34]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[35]  Troels Z. Kristiansen,et al.  Comprehensive proteomic analysis of human pancreatic juice. , 2004, Journal of proteome research.

[36]  Y. Hao,et al.  Determination of plasma glycoprotein 2 levels in patients with pancreatic disease. , 2004, Archives of pathology & laboratory medicine.

[37]  K. Bushby,et al.  Collagen VI related muscle disorders , 2005, Journal of Medical Genetics.

[38]  K. Partanen,et al.  Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[39]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[40]  Gilbert S Omenn,et al.  An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: Sensitivity and specificity analysis , 2005, Proteomics.

[41]  A. Grapin-Botton Ductal cells of the pancreas. , 2005, The international journal of biochemistry & cell biology.

[42]  S. Regnér,et al.  Active Carboxypeptidase B Is Present in Free Form in Serum from Patients with Acute Pancreatitis , 2005, Pancreatology.

[43]  M. Mann,et al.  Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.

[44]  Gilles Caraux,et al.  PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order , 2005, Bioinform..

[45]  A. Scarpa,et al.  Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  Ilan Beer,et al.  Evaluation of prefractionation methods as a preparatory step for multidimensional based chromatography of serum proteins , 2005, Proteomics.

[47]  Eugene Kolker,et al.  Randomized sequence databases for tandem mass spectrometry peptide and protein identification. , 2005, Omics : a journal of integrative biology.

[48]  Ross C. Smith,et al.  SHOULD SERUM PANCREATIC LIPASE REPLACE SERUM AMYLASE AS A BIOMARKER OF ACUTE PANCREATITIS? , 2005, ANZ journal of surgery.

[49]  Troels Z. Kristiansen,et al.  Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.

[50]  D. Chan,et al.  Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.

[51]  D. Goldenberg,et al.  New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Aebersold,et al.  Quantitative proteomic profiling of pancreatic cancer juice , 2006, Proteomics.

[53]  Ruedi Aebersold,et al.  Challenges and Opportunities in Proteomics Data Analysis* , 2006, Molecular & Cellular Proteomics.

[54]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[55]  E. Diamandis,et al.  Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients , 2006, Tumor Biology.

[56]  A. Lokshin,et al.  Multiple biomarker panels for early detection of ovarian cancer. , 2006, Future oncology.

[57]  N. Tsuji,et al.  Olfactomedin 4 promotes S‐phase transition in proliferation of pancreatic cancer cells , 2007, Cancer science.

[58]  E. Diamandis,et al.  Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.

[59]  E. Diamandis,et al.  Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.

[60]  K. Faber,et al.  Comparative proteomic analysis of human pancreatic juice: Methodological study , 2007, Proteomics.

[61]  Jiang Qian,et al.  TiGER: A database for tissue-specific gene expression and regulation , 2008, BMC Bioinformatics.

[62]  I. Petersen,et al.  Expression of AGR2 in non small cell lung cancer. , 2007, Histology and histopathology.

[63]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[64]  E. Marcotte,et al.  Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation , 2007, Nature Biotechnology.

[65]  Jean-François Hocquette,et al.  Assessment of hierarchical clustering methodologies for proteomic data mining. , 2007, Journal of proteome research.

[66]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[67]  D. Gouma,et al.  Evaluation of Matrix Metalloproteinase 7 in Plasma and Pancreatic Juice as a Biomarker for Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[68]  H. Kato,et al.  Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): Up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer , 2007, Journal of Chromatography B.

[69]  S. Satomura,et al.  Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[70]  R. Aebersold,et al.  Comparison of Pancreas Juice Proteins from Cancer Versus Pancreatitis Using Quantitative Proteomic Analysis , 2007, Pancreas.

[71]  T. Hayakawa,et al.  Enzyme immunoassay for serum pancreatic lipase in the diagnosis of pancreatic diseases , 1989, Gastroenterologia Japonica.

[72]  P. Rudland,et al.  Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients , 2007, Prostate Cancer and Prostatic Diseases.

[73]  C. Lindskog,et al.  A Web-based Tool for in Silico Biomarker Discovery Based on Tissue-specific Protein Profiles in Normal and Cancer Tissues*S , 2008, Molecular & Cellular Proteomics.

[74]  Hyungwon Choi,et al.  False discovery rates and related statistical concepts in mass spectrometry-based proteomics. , 2008, Journal of proteome research.

[75]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[76]  M. Maeda,et al.  Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. , 2008, Oncology reports.

[77]  J. Lloreta,et al.  Murine embryonic stem cell-derived pancreatic acinar cells recapitulate features of early pancreatic differentiation. , 2008, Gastroenterology.

[78]  D. Tabb,et al.  Evaluation of strong cation exchange versus isoelectric focusing of peptides for multidimensional liquid chromatography-tandem mass spectrometry. , 2008, Journal of proteome research.

[79]  Jinxiang Han,et al.  Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.

[80]  Huamin Wang,et al.  Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. , 2008, Cancer research.

[81]  E. Diamandis,et al.  Tissue culture‐based breast cancer biomarker discovery platform , 2008, International journal of cancer.

[82]  T. Bonaldi,et al.  Quantitative proteomics as a new piece of the systems biology puzzle. , 2008, Journal of proteomics.

[83]  S. Batra,et al.  Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia , 2008, British Journal of Cancer.

[84]  C. Rubie,et al.  Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases , 2008, Pancreatology.

[85]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[86]  R. Hruban,et al.  Pancreatic cancer. , 2021, Annual review of pathology.

[87]  Predrag Radivojac,et al.  HIP2: An online database of human plasma proteins from healthy individuals , 2008, BMC Medical Genomics.

[88]  M. Lerner,et al.  Biomarker Identification in Human Pancreatic Cancer Sera , 2008, Pancreas.

[89]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[90]  S. Marie,et al.  Identification of COL6A1 as a differentially expressed gene in human astrocytomas. , 2008, Genetics and molecular research : GMR.

[91]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[92]  C. Stephan,et al.  Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.

[93]  T. Colgan,et al.  Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. , 2009, Analytical chemistry.

[94]  P. Lescuyer,et al.  Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. , 2009, Journal of proteome research.

[95]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[96]  J. Winstanley,et al.  The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. , 2009, The American journal of pathology.

[97]  Markus Müller,et al.  Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? , 2009, Expert review of proteomics.

[98]  Kazuhiro Yoshida,et al.  Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients , 2009, International journal of cancer.

[99]  B. Nelson,et al.  Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia , 2010, Molecular Cancer.

[100]  E. Diamandis,et al.  Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* , 2009, Molecular & Cellular Proteomics.

[101]  F. Roviello,et al.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. , 2009, American journal of surgery.

[102]  E. Diamandis,et al.  Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. , 2009, Journal of proteome research.

[103]  A. Papalambros,et al.  CEA and CA-19.9 Serum Tumor Markers as Prognostic Factors in Patients with Locally Advanced (Unresectable) or Metastatic Pancreatic Adenocarcinoma: A Retrospective Analysis , 2009, Journal of chemotherapy.

[104]  Jinping Li,et al.  HE4 as a biomarker for ovarian and endometrial cancer management , 2009, Expert review of molecular diagnostics.

[105]  C. Pilarsky,et al.  Functional analysis of LOXL2 in pancreatic carcinoma , 2010, International Journal of Colorectal Disease.

[106]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[107]  Bhavinkumar B. Patel,et al.  Proteomic Analyses of Pancreatic Cyst Fluids , 2009, Pancreas.

[108]  Jeffrey W. Smith,et al.  Mass Spectrometry-Based Label-Free Quantitative Proteomics , 2009, Journal of biomedicine & biotechnology.

[109]  M. Neagu,et al.  Advances in pancreatic cancer detection. , 2010, Advances in clinical chemistry.

[110]  Zhuchu Chen,et al.  Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. , 2010, Cancer research.

[111]  D. Tai,et al.  Candidate Serological Biomarkers for Cancer Identified from the Secretomes of 23 Cancer Cell Lines and the Human Protein Atlas* , 2010, Molecular & Cellular Proteomics.

[112]  R. Dean,et al.  Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. , 2010, Analytical chemistry.

[113]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[114]  M. Büchler,et al.  Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology , 2010, Journal of immunotherapy.

[115]  M. Gonen,et al.  Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Annals of Surgical Oncology.

[116]  M. Girolami,et al.  Recommendations for Biomarker Identification and Qualification in Clinical Proteomics , 2010, Science Translational Medicine.

[117]  Maria P. Pavlou,et al.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.

[118]  M. Lai,et al.  Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. , 2010, Journal of proteome research.

[119]  L. Foster,et al.  Quantitative analysis of proteome coverage and recovery rates for upstream fractionation methods in proteomics. , 2010, Journal of proteome research.

[120]  T. Veenstra,et al.  Comparison of strong cation exchange and SDS-PAGE fractionation for analysis of multiprotein complexes. , 2010, Journal of proteome research.

[121]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[122]  C. Pilarsky,et al.  Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries , 2010, Cancers.

[123]  Chi Zhang,et al.  TiSGeD: a database for tissue-specific genes , 2010, Bioinform..

[124]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[125]  P. Allavena,et al.  Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks. , 2010, Journal of proteome research.

[126]  S. Hanash,et al.  The grand challenge to decipher the cancer proteome , 2010, Nature Reviews Cancer.

[127]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[128]  A. Passaniti,et al.  ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. , 2010, Cancer research.

[129]  Rosalind J. Cutts,et al.  The Pancreatic Expression database: 2011 update , 2010, Nucleic Acids Res..